The Gain from Pain Mainly Explained (part one)[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading rules and he chooses his own topics. His words and opinions are his own. Enjoy!] Lying in bed beneath an exam lamp, my 16-year-old patient’s facial serenity belied how fervently he was kneading misbaha beads with […]
Articles
- Most Relevant
- Most Recent
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month — this time, he’s covering one of the many over-hyped health ads for “secret” supplements and treatments that we all see […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
The jobs report from ADP was frightening on Wednesday, bringing more fear that the trade war uncertainty and/or some shift in sentiment is cutting business spending, and it seems to be contributing to the rapid “narrative shift” that has happened this year — whereas we were all shocked that the Fed would even consider cutting […]
These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Most investors know Muddy Waters and Carson Block, who build his short-selling investment portfolio by pulling away the veil that covered up the many China frauds several years ago, […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month. Like all of our authors, he chooses his own topics and his words and opinions are his alone. Enjoy!] Weāre talking […]
When the world looks bleak, the skies darken, and the locusts appear to be swarming on CNBC, we can always count on one thing: Newsletter editors will be trying whatever they can to convince you that they see the way forward, or that they have a safe haven for your money. Karim Rahemtulla is no […]
This article was originally posted on July 8 as part of the Friday File for the Irregulars. It has NOT been updated or revised, but we’re re-sharing it here and opening it up to all readers because we’re seeing the same ad again in heavy circulation from Dr. Kent Moors (still with a June 2016 […]
Antibiotic resistance is a big deal, as you undoubtedly already know — and resistant strains of various cooties are becoming more and more of a problem, particularly in hospital settings where they seem to spread like wildfire among the sick, infirm and open-wounded, but elsewhere as well. And the new wave of antibiotics is certainly […]
That’s a good headline, right? I pulled that quote from a Tony Daltorio ad that I saw over the weekend — and it seems to have the finger on the pulse of my nerves, at least, because combining those phrases “blue chip” and “windfall” in one sentence really give me a nice, warm feeling in […]
I think I saw this ad a few months ago and didn’t write about it for one reason or another, but it just started a heavy rotation again — so let’s have a gander. David Gardner is a growth stock dynamo — he and his brother Tom founded the Motley Fool as an AOL chat […]
[regular readers: this originally appeared last week and I’m just correcting some bad coding, sorry for any confusion] Can you really buy McDonald’s or Coca Cola for “pennies a share?” Leaving aside the fact that “pennies a share” means nothing, of course (with enough pennies, you could easily pick up some of Steve Sjuggerud’s favorite […]
“On August 1st, This Once Iconic American Retailer Will Stun Shareholders” That’s how the latest teaser ad from Harry Dent gets us interested — Dent has been around for a long time, and his predictions and books and newsletters have usually had their basis in demographics … stuff like predicting that the market would boom […]
I always love to see a new teaser from Phase 1 Investor, the high-price newsletter offered as the “ultimate upgrade” by the Stansberry & Associates folks — the stocks usually are interesting, they’re often tiny and move like crazy after the teaser campaign, and the marketing language is always plenty florid to justify the $5,000 […]
I always love to see a new teaser from Phase 1 Investor, the high-price newsletter offered as the “ultimate upgrade” by the Stansberry & Associates folks — the stocks usually are interesting, they’re often tiny and move like crazy after the teaser campaign, and the marketing language is always plenty florid to justify the $5,000 […]
A pre-emptive tease: no newsletters are yet touting this company, but like many stocks that they do tease, it is small, cheap, almost unknown, and even has the exotic appeal of being Australian. Sort of. At Stock Gumshoe we not only deconstruct pitched stocks, we find teasable stocks before the newsletters do! Letās return to […]
That “top stock” headline is the promise of Ian Wyatt, not myself, just to be clear. Wyatt and Taylor Laundon put out a letter called Top Stock Insights, the text of the ad for that letter says it’s from Taylor and the letter is “signed” by Ian Wyatt, so I guess we’ll assume it’s a […]
This article was originally published back in August, 2019 when we were getting lots of questions about Chris Wood’s teaser pitch — the ad is still largely the same, most of the hints and projections are identical and he still expects that February 2020 approval will send the stock soaring (yes, we’re still getting this […]
Today we’ve got a quickie for you, in response to a couple questions about the Cabot Top Ten Trader teaser pitch that came out over the weekend. Top Ten Trader ($137/year) is a short-term newsletter edited by Mike Cintolo, he basically sifts out ten of their favorite growth stocks each week, and I think they’re […]
The Money Map folks have decided that it’s time to go “all in” on cannabis, and for them that means starting a new investment research business that they call the National Institute for Cannabis Investors, and selling memberships in that group by teasing their favorite “special reports” on some appealing marijuana stocks that they’ll give […]
This article was originally published back in August, 2019 when we were getting lots of questions about Chris Wood’s teaser pitch — the ad is still largely the same, most of the hints and projections are identical and he still expects that February 2020 approval will send the stock soaring (yes, we’re still getting this […]
I’m still able to generate some enthusiasm about specific stocks that I think are appealing enough to buy at these prices… but I find it very hard to be optimistic in a macro sense right now, it really feels to me as though the market is whistling past the graveyard and being far too sanguine […]
Cytodyn (CYDY) is a stock that was discussed in depth here around 4 years ago. The company makes a monoclonal antibody called leronlimab (formerly known as PRO 140) which is a CCR5 inhibitor for treating HIV. The BLA has been submitted for it and the FDA has granted it fast track designation and a decision […]
How could I resist this tease? Ā Iām the guy, after all, who needs to stir his little grey cells to recall the name of that beautiful shrub growing at the northeast corner of our house. Ā Eureka, Iāve got it! ā itās called viburnum. Ā Iāve always attributed my lapses in memory to the […]
We’re used to seeing biotech stocks surge because of the results of a clinical trial… but it’s quite crazy to see the whole market pinning its hopes on a clinical trial. Gilead’s (GILD) Remdisivir had some weak results leak last week and that helped inspire the market selloff (“Oh no, we won’t get a drug […]
Here’s my soothsaying bit for this week, which you should feel free to ignore — like everyone else who’s predicting the future, I’m probably going to be wrong. I don’t think, even now, that we’re pricing in even the bad news that is already almost certain this year… or if we are, we’re pricing in […]
Sometimes when I’m choosing which ad to cover on a given day it’s based on the number of questions I’ve gotten, or the number of times we’ve seen the ad in the past few days… and sometimes it’s based on something that just feels like something interesting. Today it’s the latter… because Brett Aitken and […]
During these crazy market moves, a lot of us are keeping in the back of our mind a notion along the lines of, “hey, this might be the chance to buy something cheap… but it better be really, really good!” And for many of us, that means our minds drift to “blue chip” type stocks […]
Thank you for coming back and reading my musings week after week, we here at Stock Gumshoe would not exist if not for the attention and generosity of readers like you. I don’t say it enough, I’m sure, but I really appreciate you being with us… and having the patience to slog through these sometimes […]
It’s been a wild week. The mood was still pretty upbeat on Monday and Tuesday, a little anxiety but a lot of complacency (including mine)… I was in Toronto early this week, with plenty of hand washing and hand sanitizer but no real signs of panic or changes in lifestyle for most folks — the […]
This is not a for sure thing. But something to watch if you are investing in GPU stocks like NVIDIA (which I have used for many years). The use of the CPU has the potential to lower costs and cooling for deep learning. (Good for Intel and AMD and a negative influence on Nvidia). (NOTE: […]
It’s been an unusually active month in the Real Money Portfolio — a couple big sells, several brand new positions, and quite a bit more churn than I usually have. Those transactions have mostly been fairly small, the largest position that I opened or closed was the sale of my sub-2% Facebook position, but that’s […]
This article was originally published on January 6, 2020. Neither the ad we’re covering nor this article has been updated since then, though I’ve added a small update note at the end. The stock is back to where it was before the first promo pitch was mailed, and the latest emails pointing to this teaser […]
wow just read the indictment against Huawei by the Grand Jury see here https://www.documentcloud.org/documents/6775682-Huawei-Superseding-Indictment.html?utm_source=market-sum&utm_campaign=www.investopedia.com&utm_term=19442358&utm_medium=email If only 10% of this sticks Huawei will be in real trouble. I wonder if this will prompt a rating by British authorities about there decision re Huawei. It sort of reads like a compendium of illegal activities all in one.. […]
Growth stocks get all the attention these days, what with talk of a final “melt up” in the market before things finally return to rationality, and “value stocks” have been floundering for years as they’ve failed to capture the attention of investors… so last fall we saw a lot of predictions about the “turn,” the […]
So… what’s a “Q-Share?” Are they some magical kind of stock that you can buy, through some secret method, that’s much better than the dumb old regular kinds of stocks you have in your brokerage account? Um, sadly, no… not really — but there is a rationale worth investigating here, and a secret stock to […]
Please indulge Doc Gumshoe while he presents his musings on whatās going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw. Ā My impressions and conclusions are in some cases only loosely based on […]
Heydy ho, Gumshoe friends… today I’m going to go a little over my allotted time, this is the last Friday File for 2019 so I’m going to throw in a teaser solution for you first, then go over some updates and changes and news items from the Real Money Portfolio… ready? The teaser that some […]
The headline that snagged my attention was this:Ā āThirty-five Thousand Americans Die of Antibiotic-Resistant Infections Each Yearā This was based on the Centers for Disease Controlās Antibiotic Resistance Threats in the United States, 2019, which led off with the statement that more than 2.8 million antibiotic-resistant infections occur in the US every year, and more […]
A quickie for you today, since a few folks have asked… One of the seemingly 10,000 Banyan Hill newsletters is being teased today, and the bait they’re dangling is that Jeff Yastine is about to recommend a stock to his subscribers on Wednesday… which is tomorrow, so we’ll be brief so you can have some […]